Galmed Pharmaceuticals Ltd.
General ticker "GLMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2M (TTM average)
Galmed Pharmaceuticals Ltd. does not follow the US Stock Market performance with the rate: -5.3%.
Estimated limits based on current volatility of 4.4%: low 0.99$, high 1.08$
Factors to consider:
- Total employees count: 15 as of 2014
- Current price 30.1% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.62$, 5.56$]
- 2025-12-31 to 2026-12-31 estimated range: [1.12$, 3.96$]
Financial Metrics affecting the GLMD estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -205.69 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 88.25 > 63.39
- Positive: Interest expense per share per price, % of 0.52 <= 0.79
Short-term GLMD quotes
Long-term GLMD plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $14.98MM | $0.00MM |
| Operating Expenses | $17.65MM | $7.49MM | $6.28MM |
| Operating Income | $-17.65MM | $7.49MM | $-6.28MM |
| Non-Operating Income | $-0.21MM | $-14.40MM | $-1.24MM |
| Interest Expense | $0.21MM | $0.01MM | $0.01MM |
| R&D Expense | $12.99MM | $3.57MM | $2.98MM |
| Income(Loss) | $-17.87MM | $-6.91MM | $-7.52MM |
| Profit(Loss)* | $-18.57MM | $-6.91MM | $-7.52MM |
| Stockholders Equity | $13.42MM | $13.88MM | $16.33MM |
| Inventory | $0.11MM | $0.00MM | $0.00MM |
| Assets | $16.56MM | $16.63MM | $18.50MM |
| Operating Cash Flow | $-18.50MM | $-6.14MM | $-5.88MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $17.56MM | $0.80MM | $-1.11MM |
| Financing Cash Flow | $0.07MM | $6.18MM | $8.79MM |
| Earnings Per Share** | $-11.08 | $-30.05 | $-8.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.